Annexon (NASDAQ: ANNX) updates corporate deck for J.P. Morgan

Rhea-AI Filing Summary

Annexon, Inc. reported that it has updated its corporate investor presentation to reflect certain business and strategic updates. The revised presentation, dated January 14, 2026, may be used in upcoming meetings with analysts and investors, including at the 44th Annual J.P. Morgan Healthcare Conference. It will also be available in the Investors & Media section of the company's website.

The investor presentation is furnished as Exhibit 99.1 under Item 7.01 and is expressly stated as being furnished, not filed, which means it is not subject to certain liability provisions of the securities laws and is not automatically incorporated into other Securities and Exchange Commission documents.

false 0001528115 0001528115 2026-01-14 2026-01-14

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 14, 2026

ANNEXON, INC.

(Exact name of registrant as specified in its charter)

Delaware		001-39402		27-5414423
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

1400 Sierra Point Parkway, Bldg C, Suite 200 Brisbane, California				94005
(Address of principal executive offices)				(Zip Code)

Registrant’s telephone number, including area code: (650) 822-5500

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.001 per share		ANNX		The Nasdaq Stock Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure.

On January 14, 2026, Annexon, Inc. (the “Company”) updated its corporate presentation to reflect certain business and strategic updates. The presentation may be used in upcoming meetings with analysts and investors, including at the 44^th Annual J.P. Morgan Healthcare Conference, and will also be available in the “Investors & Media” section of the Company’s website at ir.annexonbio.com. A copy of the presentation is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein. The Company’s website and any information contained on the Company’s website are not incorporated by reference into this Current Report on Form 8-K.

The information furnished under this Item 7.01 (including Exhibit 99.1), shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information in this Item 7.01 (including Exhibit 99.1) shall not be deemed incorporated by reference into any filing with the Securities and Exchange Commission made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing, except as expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.		Description
99.1		Investor Presentation dated January 14, 2026.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

				Annexon, Inc.
Date: January 14, 2026				By:		/s/ Jennifer Lew
						Jennifer Lew
						Executive Vice President and Chief Financial Officer

FAQ

What did Annexon (ANNX) disclose in this 8-K report?

Annexon disclosed that it has updated its corporate investor presentation to reflect certain business and strategic updates and is furnishing it as Exhibit 99.1.

What is included in Annexon's Exhibit 99.1?

Exhibit 99.1 is an investor presentation dated January 14, 2026, containing updated corporate, business, and strategic information.

Where can investors access Annexon's updated investor presentation?

The updated investor presentation will be available in the Investors & Media section of Annexon's website at ir.annexonbio.com.

For what event may Annexon use the updated presentation?

Annexon may use the updated presentation in meetings with analysts and investors, including at the 44th Annual J.P. Morgan Healthcare Conference.

Is the information in Annexon's investor presentation considered filed with the SEC?

No. The information furnished under Item 7.01, including Exhibit 99.1, is expressly stated as furnished, not filed, and is not subject to Section 18 of the Exchange Act.

Does Annexon's investor presentation automatically become part of other SEC documents?

No. The company states that the information in Item 7.01 and Exhibit 99.1 is not incorporated by reference into any other SEC filing unless specifically referenced.